...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine.
【24h】

Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine.

机译：晚期胃癌术后辅助放化疗的初步研究：辅助5-FU /顺铂和卡培他滨的化学放疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To evaluate the efficacy and toxicity of postoperative chemoradiation using FP chemotherapy and oral capecitabine during radiation for advanced gastric cancer following curative resection. METHODS: Thirty-one patients who had underwent a potentially curative resection for Stage III and IV (M0) gastric cancer were enrolled. Therapy consists of one cycle of FP (continuous infusion of 5-FU 1000 mg/m(2) on d 1 to 5 and cisplatin 60 mg/m(2) on d 1) followed by 4500 cGy (180 cGy/d) with capecitabine (1650 mg/m(2) daily throughout radiotherapy). Four wk after completion of the radiotherapy, patients received three additional cycles of FP every three wk. The median follow-up duration was 22.2 mo. RESULTS: The 3-year disease free and overall survival in this study were 82.7% and 83.4%, respectively. Four patients (12.9%) showed relapse during follow-up. Eight patients did not complete all planned adjuvant therapy. Grade 3/4 toxicities included neutropenia in 50.2%, anemia in 12.9%, thrombocytopenia in 3.2%and nausea/vomiting in 3.2%. Neither grade 3/4 hand foot syndrome nor treatment related febrile neutropenia or death were observed. CONCLUSION: These preliminary results suggest that this postoperative adjuvant chemoradiation regimen of FP before and after capecitabine and concurrent radiotherapy appears well tolerated and offers a comparable toxicity profile to the chemoradiation regimen utilized in INT-0116. This treatment modality allowed successful loco-regional control rate and 3-year overall survival.
机译：目的：为了评估根治性切除术后晚期胃癌放疗期间使用FP化疗和口服卡培他滨的术后化学放疗的疗效和毒性。方法：招募了31例行III期和IV期（M0）胃癌根治性切除术的患者。治疗包括一个周期的FP（在第1至5天连续输注5-FU 1000 mg / m（2），在第1天连续输注顺铂60 mg / m（2）），然后进行4500 cGy（180 cGy / d）的治疗卡培他滨（整个放疗期间每天1650 mg / m（2））。放疗完成后四周，患者每三周接受三个额外的FP周期。中位随访时间为22.2 mo。结果：本研究的3年无病生存率和总生存率分别为82.7％和83.4％。随访期间有4例患者（12.9％）复发。 8名患者未完成所有计划的辅助治疗。 3/4级毒性包括中性粒细胞减少症50.2％，贫血12.9％，血小板减少症3.2％和恶心/呕吐3.2％。既没有观察到3/4级手足综合征，也没有观察到与治疗有关的发热性中性粒细胞减少或死亡。结论：这些初步结果表明，在卡培他滨和同时放疗前后FP的这种术后辅助化学放疗方案耐受性良好，并且毒性与INT-0116中使用的化学放疗方案相当。这种治疗方式允许局部区域成功控制率和3年总生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号